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L-ascorbic acid 2-phosphate promotes 
elongation of hair shafts via the secretion  
of insulin-like growth factor-1  
from dermal papilla cells through 
phosphatidylinositol 3-kinase
Is the promotion of hair growth by L-ascorbic acid 2-phos-
phate (Asc 2-P) mediated by insulin-like growth fac-
tor-1 (IGF-1) and if so, what is the mechanism of the Asc 
2-P-induced IGF-1 expression? Dermal papilla (DP) cells 
were cultured and IGF-1 level was measured by RT-PCR 
and ELISA after Asc 2-P treatment in the absence or pres-
ence of LY294002, a phosphatidylinositol 3-kinase (PI3K) 
inhibitor. Also, hair shaft elongation in cultured human 
scalp hair follicles and proliferation of co-cultured kera-
tinocytes were examined after Asc 2-P treatment in the 
absence or presence of neutralizing IGF-1 antibody. In 
addition, keratinocyte proliferation in cultured hair fol-
licles after Asc 2-P treatment in the absence or presence 
of LY294002 was examined by Ki-67 immunostaining. The 
study showed that Asc 2-P-inducible IGF-1 from DP cells 
promotes proliferation of follicular keratinocytes and stim-
ulates hair follicle growth in vitro via PI3K. Br J Dermatol 
2009; 160:1157–62.
IL-4/IL-13 antagonist DNA vaccination 
successfully suppresses Th2 type  
chronic dermatitis
Atopic dermatitis (AD) is a chronic disease with Th2-type-
cytokine dominant profile. Several cytokines and related 
peptides have been used for the treatment of AD but they 
were ineffective because of limitation in their biological 
half time. This study examined the effects of IL-4DM in vivo 
AD model induced by repeated elicitation of oxazolone 
(OX). Plasmid DNA was injected intraperitoneally on an 
experimental AD-like dermatitis. The effect was evaluat-
ed by ear thickness, histological findings, and mast cells 
counts in the inflamed skin. Plasma IgE and histamine 
level was measured. Cytokine production in skin and sple-
nocytes was also analyzed. The present data showed that 
simultaneous suppression of IL-4/IL-13 signal successfully 
controlled Th2-type chronic dermatitis. IL-4DM DNA treat-
ment could be a potent therapy for AD and related diseas-
es. Br J Dermatol 2009; 160:1172–9.
Neonatal colonization with Staphylococcus 
aureus is not associated with development  
of atopic dermatitis
The purpose of this study was to investigate a possible asso-
ciation between neonatal colonization with S. aureus and 
the risk of atopic dermatitis (AD) during the first 3 years 
of life. 356 children born of mothers with asthma from the 
Copenhagen Prospective Study on Asthma in Childhood 
participated. Swabs from vestibulum nasi and perineum 
were cultured at 1 month, 1 year, from acute eczema, and 
from parents (vestibulum nasi and pharynx). AD develop-
ment and severity were monitored prospectively. They 
found that colonization with S. aureus at 1 month of age 
was not associated with an increased risk of develop-
ing AD during the first 3 years of life. Br J Dermatol 2009; 
160:1286–91.
Bexarotene therapy for mycosis fungoides 
and Sézary syndrome
In this retrospective study we summarise our experience 
with Bexarotene (Targretin®) for patients with cutaneous 
T-cell lymphoma (CTCL) with the aim of assessing effi-
cacy and safety. In all, 66 patients (44 male, 22 female) 
with mycosis fungoides (40 patients) or Sézary syndrome 
(26 patients) were commenced on bexarotene prior to 
August 2007. 19 patients had early stage (IB-IIA) refrac-
tory mycosis fungoides and 47 patients had advanced 
stage CTCL (IIB-IVB). 52/66 (79%) patients completed 
over 1 month’s therapy with an intention to treat response 
rate of 44% (29/66). Of these patients, 6 (9%) had a com-
plete response, 23 (35%) had a partial response, 15 (23%) 
had stable disease and 8 (12%) had progressive disease. 
Median time to maximal response was 3 months (1–9). 
Median response duration was 8 months (1≥48). Median 
time to progression was 9 months (3–44). Adverse effects 
included hypothyroidism in 100%, managed with thyroid 
replacement, and hyperlipidaemia in 100%, managed with 
lipid lowering therapy ± dose reduction. Br J Dermatol 
2009; 160:1299–307.
Photodynamic therapy of actinic keratoses 
with 8% and 16% methyl aminolaevulinate 
and home-based daylight exposure:  
a double-blinded randomized clinical trial
Response rates and adverse effects after photo dynamic 
therapy (PDT) using conventional 16% and 8% methyl ami-
nolevulinate (MAL) was compared with home-based day-
light exposure in treatment of actinic keratosis (AK). Thirty 
patients with mostly thin grade AK of the face or scalp were 
treated with 16% and 8% MAL-PDT in two symmetric areas 
after application of sunscreen. Immediately after, patients 
left the hospital with instructions to spend the remaining 
day outside at home in daylight. Patients scored pain during 
treatment and light exposure was monitored with an elec-
tronic wristwatch dosimeter. Home-based daylight-mediat-
ed MAL-PDT was an effective and well-tolerated treatment 
of AK. No differences in response rates or adverse events 
were found between the 16% and 8% MAL treated areas. 
Br J Dermatol 2009; 160:1308–14.
